Nektar Therapeutics | NKTR - Current Assets


Nektar Therapeutics reported $589.04M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
ALKERMES USD 1.58B 57.83M Sep/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Amgen USD 34.36B 598M Sep/2026
Baxter International USD 6.83B 163M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Cara Therapeutics USD 25.33M 6.21M Mar/2026
Cipla INR 250.61B 9.14B Sep/2026
Dr.Reddys Laboratories INR 297.32B 2.01B Sep/2026
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 65.26B 591M Sep/2026
Exelixis USD 1.32B 70.8M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Ironwood Pharmaceuticals USD 225.99M 26.79M Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck USD 38.94B 2.26B Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Takeda JPY 3T 153.11B Sep/2026
Teva Pharmaceutical Industries USD 14.6B 842M Sep/2026
Xencor USD 498.66M 24.55M Sep/2026